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Introduction {#prp2237-sec-0001}
============

Type 2 diabetes mellitus (T2DM) is a chronic and progressive disease with two major causes; insulin resistance and pancreatic *β*‐cell dysfunction. Several drug classes have been developed for the treatment of T2DM including sulfonylureas (SUs), biguanides (i.e., metformin), *α*‐glucosidase inhibitors, glitazones, dipeptidyl peptidase‐4 (DPP‐4) inhibitors, glucagon‐like peptide‐1 (GLP‐1) analogs, and recently approved sodium/glucose cotransporter‐2 (SGLT‐2) inhibitors (Inzucchi et al. [2012](#prp2237-bib-0015){ref-type="ref"}; American Diabetes Association, [2015](#prp2237-bib-0002){ref-type="ref"}). Among these drugs, SUs are utilized frequently after initial lifestyle intervention and metformin therapy. However, the use of SUs is accompanied by an inherent risk of uncontrollable hypoglycemia because they stimulate insulin secretion independently of the blood glucose concentration. DPP‐4 inhibitors and GLP‐1 analogs can overcome this drawback of SUs, but they are unable to achieve sufficient blood glucose control in many patients (American Diabetes Association, [2015](#prp2237-bib-0002){ref-type="ref"}). Therefore, a novel drug with less risk of inducing hypoglycemia is desirable.

Fasiglifam (TAK‐875) is an orally absorbed novel antidiabetic agent that enhances insulin secretion in a glucose‐dependent manner (Negoro et al. [2010](#prp2237-bib-0026){ref-type="ref"}, [2012](#prp2237-bib-0027){ref-type="ref"}). Fasiglifam is an ago‐allosteric modulator of free fatty acid receptor 1 (FFAR1; also known as G‐protein--coupled receptor 40, (GPR40)) and potentiates insulin secretion in synergy with FFAs (Yabuki et al. [2013](#prp2237-bib-0037){ref-type="ref"}), supported by the result of the X‐ray cocrystal structure demonstrating the unique binding of fasiglifam on FFAR1 (Srivastava et al. [2014](#prp2237-bib-0034){ref-type="ref"}). Both the preclinical and clinical studies achieved the improved glycemic control in rodents and human patients with a minimal risk of hypoglycemia (Tsujihata et al. [2011](#prp2237-bib-0035){ref-type="ref"}; Burant et al. [2012](#prp2237-bib-0006){ref-type="ref"}; Kaku et al. [2015](#prp2237-bib-0018){ref-type="ref"}). Although such a satisfactory benefit--risk profile of fasiglifam is brought by its strict glucose‐dependent action on insulin release, the underlying mechanism of the dependence remains unknown.

FFAR1 couples mainly with G*α*q protein, and the resulting signal cascade is important for insulin secretion, as is the case with muscarinic receptor subtype M~3~ (Gilon and Henquin [2001](#prp2237-bib-0012){ref-type="ref"}; Sassmann et al. [2010](#prp2237-bib-0030){ref-type="ref"}). Inositol 1,4,5‐triphosphate (IP~3~) and diacylglycerol (DAG) are well‐known second messengers that activate different signaling pathways; that is*,* IP~3~ interacts with its receptor on the endoplasmic reticulum (ER) increasing the intracellular Ca^2+^ concentration, whereas DAG activates protein kinase C (PKC). But their individual contribution and interdependence in potentiating insulin secretion are not fully described.

In this study, we investigated interactions between G*α*q signaling activated by fasiglifam and insulin secretory pathways, focusing on insulin release and Ca^2+^ oscillations. Pancreatic *β*‐cells exhibit Ca^2+^ oscillations of variable frequency and amplitude, triggering pulsatile insulin release (Liu et al. [1998](#prp2237-bib-0021){ref-type="ref"}; Nunemaker et al. [2006](#prp2237-bib-0028){ref-type="ref"}). We thus compared different oscillatory patterns when stimulated with fasiglifam and a SU glimepiride by decoding the signals using fast Fourier transforms (FFT). We previously reported that IP~3~ production by fasiglifam was not dependent on glucose concentration but intracellular Ca^2+^ concentration was tangibly glucose dependent (Tsujihata et al. [2011](#prp2237-bib-0035){ref-type="ref"}), thereby extending the efficacy of IP~3~ on insulin secretion and Ca^2+^ oscillations using cell‐permeable IP~3~ analog. Also, roles of DAG on insulin secretion and Ca^2+^ dynamics are examined by DAG analog combined with Ca^2+^ influx using an L‐type voltage‐dependent calcium channels (VDCC) opener.

Materials and Methods {#prp2237-sec-0002}
=====================

Reagents {#prp2237-sec-0003}
--------

### Fasiglifam {#prp2237-sec-0004}

(\[(*3S*)‐6‐({2′,6′‐dimethyl‐4′‐\[3‐(methylsulfonyl)propoxy\]biphenyl‐3‐yl}methoxy)‐2,3‐dihydro‐1‐benzofuran‐3‐yl\]acetic acid hemihydrate) was synthesized at Takeda Pharmaceutical Company (Osaka, Japan). Diazoxide, KCl, and glimepiride were purchased from Wako Pure Chemical Industries (Osaka, Japan). Sterile D‐(+)‐glucose solution (45% in water), *γ*‐linolenic acid (*γ*‐LA), and *(S)*‐(‐)‐Bay K8644 were purchased from Sigma‐Aldrich (St. Louis, MO). D‐myo‐inositol 1,3,5‐trisphosphate hexakisacetoxymethyl ester, 2,4,6‐tri‐O‐butyryl (Bt~3~IP~3~), a cell‐permeable derivative of D‐myo‐inositol 1,3,5‐trisphosphate, was purchased from Merck Millipore (Tokyo, Japan). A cell‐permeable analog of DAG, 1‐oleoyl‐2‐acetyl‐*sn*‐glycerol (OAG), was purchased from Cayman Chemical (Ann Arbor, MI). Nifedipine was purchased from MP Biomedicals (Tokyo, Japan). Krebs‐Ringer‐bicarbonate‐HEPES (KRBH) buffer (116 mmol/L NaCl, 4.7 mmol/L KCl, 1.17 mmol/L KH~2~PO~4~, 1.17 mmol/L MgSO~4~, 25 mmol/L NaHCO~3~, 2.52 mmol/L CaCl~2~, and 24 mmol/L HEPES (pH 7.4)) containing 0.2% bovine serum albumin (BSA) was freshly prepared before each experiment. Fura‐2 acetoxymethyl ester was purchased from Dojindo Laboratories (Kumamoto, Japan).

Cell lines {#prp2237-sec-0005}
----------

MIN6 cells (Miyazaki et al. [1990](#prp2237-bib-0025){ref-type="ref"}) were provided by Dr. Miyazaki (Osaka University) and grown in Dulbecco\'s Modified Eagle Medium containing 10% heat‐inactivated fetal bovine serum, 100 IU/mL penicillin, 100 *μ*g/mL streptomycin, and 55 *μ*mol/L 2‐mercaptoethanol (Life Technologies, Tokyo, Japan). Cells were cultured at 37°C in a humidified atmosphere containing 5% CO~2~/95% air.

Insulin secretion assay {#prp2237-sec-0006}
-----------------------

MIN6 cells were seeded at a density of 6 × 10^4^ cells/well in 96‐well plates and cultured for 2 days before each experiment. After the medium was discarded, cells were preincubated for 2 h at 37°C with KRBH buffer containing 0.2% BSA and 1 mmol/L glucose. The preincubation buffer was then discarded and KRBH‐containing 0.2% BSA, various concentrations of glucose, and stimulators/inhibitors as shown were added. The plate was then incubated for 2 h at 37°C. Supernatants from each well were collected and the insulin concentration was measured using AlphaLISA Human Insulin Immunoassay kit (PerkinElmer, Waltham, MA) following the manufacturer\'s instructions.

Ca^2+^ imaging assay {#prp2237-sec-0007}
--------------------

MIN6 cells were seeded at a density of 1.5 × 10^5^ cells/well in an eight‐well Nunc Lab‐Tek Chamber Slide System (Thermo Scientific, Tokyo, Japan), and cultured for 3--5 days. After removing the medium, cells were loaded with 5 *μ*mol/L fura‐2 acetoxymethyl (AM) ester in 1× Hank\'s Balanced Salt Solution (prepared in our laboratory according to standard protocols, and supplemented with various concentrations of glucose and 20 mmol/L HEPES buffer) for 45 min at 37°C, and washed three times with Hank\'s Balanced Salt Solution. Chambers were then mounted on the microscope stage (Eclipse Ti, Nikon, Tokyo, Japan). Cells were imaged for 5 min with an Aquacosmos ratio imaging system (Hamamatsu, Shizuoka, Japan). Ligand was added at 2.5 min after recording started. Using excitation wavelengths of 340 and 380 nm, changes in fluorescence intensity of fura‐2 AM were acquired every 0.5 sec at 535 nm. The fluorescence intensity ratios (340/380 nm) were calculated using Aquacosmos software (Hamamatsu, Shizuoka, Japan). Changes in the intracellular Ca^2+^ level were determined using the ratio of the area under the curve (AUC) between 1 min before and 1 min after ligand stimulation ("Post/Pre"). For spectral analysis, FFT was used to change the time unit to frequency. To obtain the power spectrum density (PSD), the Fourier transform was squared and normalized by dividing by *N* (128 time points). These methods were modified from a previous report (Uhlen [2004](#prp2237-bib-0036){ref-type="ref"}).

Data analysis and statistics {#prp2237-sec-0008}
----------------------------

To determine statistical significance for potentiation, Welch\'s *t*‐test or ANOVA followed by Dunnett\'s multiple‐comparison test were performed at the significance level of *P* \< 0.05. To show synergistic interaction between two factors, we conducted a two‐way ANOVA with a significance level of *P* \< 0.05 followed by a post hoc test using Williams' test. To test the dose--response relationships, Bartlett\'s test was conducted at *P* \< 0.05 and Williams or Shirley--Williams tests were conducted at the one‐tailed significance level of *P* \< 0.025. All statistical analyzes were performed using Statistical Analysis System version 9.3 (SAS Institute, Cary, NC).

Results {#prp2237-sec-0009}
=======

Membrane depolarization of *β*‐cells is necessary for the insulinotropic effect of fasiglifam {#prp2237-sec-0010}
---------------------------------------------------------------------------------------------

Membrane depolarization is a fundamental event in the integration of excitatory signals during glucose‐induced insulin secretion (MacDonald and Rorsman [2006](#prp2237-bib-0022){ref-type="ref"}; Drews et al. [2010](#prp2237-bib-0008){ref-type="ref"}). Thus, we examined whether the glucose‐dependent insulinotropic effect of fasiglifam was affected by the K~ATP~ channel opener diazoxide or exogenous high K^+^ that prevents or induces membrane depolarization. In the presence of 100 *μ*mol/L diazoxide, the potentiating effect of fasiglifam on glucose‐stimulated insulin secretion (GSIS) was completely abolished in MIN6 cells (Fig. [1](#prp2237-fig-0001){ref-type="fig"}A). In contrast, in the presence of 10 mmol/L KCl without glucose, fasiglifam augmented insulin secretion (Fig. [1](#prp2237-fig-0001){ref-type="fig"}B). These results reinforce the significance of membrane depolarization for the insulinotropic action of fasiglifam.

![Membrane depolarization is essential and sufficient for fasiglifam to exert its insulinotropic effect. (A) Effects of diazoxide on the glucose‐stimulated insulin secretion (GSIS)‐potentiating effect of fasiglifam in mouse MIN6 cells. Data are normalized to the vehicle (0 mmol/L glucose) group and shown as means ± SEM (*n* = 3). \*\*\**P* \< 0.001 versus 0 mmol/L glucose by Dunnett\'s test. ^\$^ *P* \< 0.05 by Welch\'s *t*‐test. (B) Effect of fasiglifam on KCl‐induced depolarization‐mediated insulin secretion in MIN6 cells. Data are normalized to the vehicle (no KCl) group and shown as means ± SEM (*n* = 3). \*\*\**P* \< 0.001 versus vehicle group by Dunnett\'s test. ^\$\$^ *P* \< 0.01 by Welch\'s *t*‐test.](PRP2-4-e00237-g001){#prp2237-fig-0001}

Both the IP~3~/Ca^2+^ and DAG/PKC pathways downstream of FFAR1 contribute to the insulinotropic effect of fasiglifam {#prp2237-sec-0011}
--------------------------------------------------------------------------------------------------------------------

The roles of second messengers downstream of FFAR1 on the insulin potentiating effects of fasiglifam were examined. Consistent with our previous reports (Tsujihata et al. [2011](#prp2237-bib-0035){ref-type="ref"}; Yabuki et al. [2013](#prp2237-bib-0037){ref-type="ref"}), fasiglifam, alone and in combination with *γ*‐LA, enhanced GSIS in MIN6 cells in a glucose‐dependent manner (Fig. [2](#prp2237-fig-0002){ref-type="fig"}A). Because stimulation of G*α*q‐coupled FFAR1 activates the IP~3~/Ca^2+^ and DAG/PKC pathways, we next investigated the roles of these two signaling branches on the potentiation of GSIS. Both Bt~3~IP~3~/AM and OAG augmented GSIS (Fig. [2](#prp2237-fig-0002){ref-type="fig"}B and C), indicating that two distinct pathways could play a role in the potentiation of insulin secretion.

![Both IP~3~‐mediated Ca^2+^ release from ER, and protein kinase C (PKC) activation downstream of FFAR1 contribute to the glucose‐stimulated insulin secretion (GSIS) potentiating effect of fasiglifam. (A) Potentiating effects of fasiglifam and *γ*‐linolenic acid on GSIS in MIN6 cells. Data are normalized to the vehicle (0 mmol/L glucose) group and shown as means ± SEM (*n* = 3). \*\**P* \< 0.01, \**P* \< 0.05, by Dunnett\'s test. (B) Effect of IP~3~ receptor activation by Bt~3~IP~3~ on GSIS in MIN6 cells. Data are normalized to the vehicle (0 mmol/L glucose) group and shown as means ± SEM (*n* = 3). Two‐way ANOVA: main effect of glucose: *P* \< 0.01; main effect of Bt~3~IP~3~: *P* \< 0.01; interaction of glucose and Bt~3~IP~3~: *P* \< 0.01. \**P* \< 0.05 by Welch\'s *t*‐test. (C) Effect of PKC activation by OAG on GSIS in MIN6 cells. Data are normalized to the vehicle (0 mmol/L glucose group) and shown as means ± SEM (*n* = 3). Two‐way ANOVA: main effect of glucose: *P* \< 0.01; main effect of OAG: *P* \< 0.01; interaction of glucose and OAG: *P* \< 0.01. \*\**P* \< 0.01 by Welch\'s *t*‐test.](PRP2-4-e00237-g002){#prp2237-fig-0002}

Fasiglifam induces a glucose‐dependent increase in intracellular Ca^2+^ and amplified Ca^2+^ oscillations {#prp2237-sec-0012}
---------------------------------------------------------------------------------------------------------

Ionic or action potential dynamics are determinants of pulsatile insulin secretion (Bergsten [1995](#prp2237-bib-0004){ref-type="ref"}; MacDonald and Rorsman [2006](#prp2237-bib-0022){ref-type="ref"}). Thus, we investigated the effect of fasiglifam on Ca^2+^ dynamics. Addition of fasiglifam elevated the intracellular Ca^2+^ level in MIN6 cells in a glucose‐dependent manner (Fig. [3](#prp2237-fig-0003){ref-type="fig"}A and B). In addition, fasiglifam enhanced the amplitude of Ca^2+^ oscillation waves in a glucose‐dependent manner (Fig. [3](#prp2237-fig-0003){ref-type="fig"}C). Differences in bandwidths of Ca^2+^ waves affect the distinct phenotype of *β*‐cells; that is*,* short bandwidths couple mainly to *β*‐cells metabolism such as glycolytic activity, whereas long bandwidths couple to ion channel activity required for Ca^2+^‐triggered exocytosis (Liu et al. [1998](#prp2237-bib-0021){ref-type="ref"}; Bergsten [2002](#prp2237-bib-0005){ref-type="ref"}). Moreover, some genes, such as those coding for the transient receptor potential cation channel, subfamily M, member 5 (TRPM5), and the *β*3 subunit of L‐type VDCC, have been linked to certain oscillatory bandwidths (Berggren et al. [2004](#prp2237-bib-0003){ref-type="ref"}; Colsoul et al. [2010](#prp2237-bib-0007){ref-type="ref"}). Therefore, we analyzed the variability in Ca^2+^ waves using FFT by subdividing them into three bandwidths (\~100, \~200, and \~1000 mHz). The results showed that fasiglifam affected the amplitude modulation in all three bandwidths, and had no effects on the modulation of certain frequencies (Fig. [3](#prp2237-fig-0003){ref-type="fig"}C). We then addressed the effects of glimepiride that augments insulin secretion independently of glucose, on intracellular Ca^2+^ dynamics. Intriguingly, glimepiride induced robust increases in Ca^2+^ levels and oscillations irrespective of the glucose concentration (Fig. [3](#prp2237-fig-0003){ref-type="fig"}D--F). These results clearly demonstrated that the glucose‐dependent regulation of intracellular Ca^2+^ by fasiglifam was distinct from glimepiride.

![Effect of fasiglifam and glimepiride on glucose‐dependent and ‐independent increases in intracellular Ca^2+^ level and Ca^2+^ oscillations. Ca^2+^ dynamics were determined in MIN6 cells loaded with fura‐2 AM and stimulated with (A--C) fasiglifam or (D--E) glimepiride. (A), (D) Representative traces in 21 regions of interest in one experiment at the indicated glucose concentrations. (B), (E) Changes in the intracellular Ca^2+^ response quantified by the area under the curve 1 min before and 1 min after stimulation. Data are presented as means ± SEM of 63 regions of interest within three experiments. (C), (F) Power spectrum density profiles describing the power of the oscillations at different frequencies generated by fast Fourier transform. Power is proportional to amplitude squared. The results were subclassified into three groups: low (1--100 mHz), middle (101--200 mHz), and high (201--1000 mHz). The Nyquist frequency in these experiments is about 1000 mHz. Data are expressed as means ± SEM of 63 regions of interest within three experiments. \#*P* \< 0.025 versus 0 mmol/L glucose by one‐tailed Williams' test. \**P* \< 0.05, \*\**P* \< 0.01 by Welch\'s *t*‐test.](PRP2-4-e00237-g003){#prp2237-fig-0003}

An IP~3~ analog enhances Ca^2+^ oscillations similar to fasiglifam, whereas a DAG analog has no effect {#prp2237-sec-0013}
------------------------------------------------------------------------------------------------------

Intracellular Ca^2+^ dynamics in pancreatic *β*‐cells are regulated by two main sources: (1) Ca^2+^ release from intracellular Ca^2+^ stores, and (2) extracellular Ca^2+^ influx through Ca^2+^ channels. Both sources can occur in response to an extracellular stimulus. IP~3~, a downstream messenger of FFAR1, elicits Ca^2+^ release from the ER (Gwiazda et al. [2009](#prp2237-bib-0014){ref-type="ref"}). To investigate the role of IP~3~ on Ca^2+^ dynamics, we monitored the effect of its analog, Bt~3~IP~3~/AM, on MIN6 cells. Bt~3~IP~3~/AM augmented Ca^2+^ dynamics in a glucose‐dependent way, similar to fasiglifam (Fig. [4](#prp2237-fig-0004){ref-type="fig"}A--C). These results demonstrate a critical role of the IP~3~/Ca^2+^ pathway in increasing intracellular Ca^2+^ levels and enhancing the amplitude of Ca^2+^ oscillations, both of which may contribute to enhanced insulin secretion.

![Effects of Bt~3~IP~3~ and OAG on glucose‐dependent intracellular Ca^2+^ dynamics. Detailed analyzes of Ca^2+^ dynamics were performed in MIN6 cells loaded with fura‐2 AM and stimulated with (A--C) Bt~3~IP~3~ or (D--E) OAG. (A), (D) Representative traces in 21 regions of interest in one experiment at the indicated glucose concentrations. (B), (E) Changes in the intracellular Ca^2+^ response quantified by the area under the curve 1 min before and 1 min after stimulation. Data are presented as means ± SEM of 63 regions of interest within three experiments. (C), (F) Power spectrum density profiles describing the power of the oscillations at different frequencies generated by fast Fourier transform. The mathematical conditions are the same as in Figure [3](#prp2237-fig-0003){ref-type="fig"}. Data are expressed as means ± SEM of 63 regions of interest within three experiments. ^\#^ *P* \< 0.025 versus 0 mmol/L glucose by one‐tailed Williams' test. \**P* \< 0.05, \*\**P* \< 0.01 by Welch\'s *t*‐test.](PRP2-4-e00237-g004){#prp2237-fig-0004}

The effect of the DAG/PKC pathway on Ca^2+^ dynamics was assessed by using the DAG analog, OAG. In contrast to fasiglifam and Bt~3~IP~3~/AM, OAG did not affect either the intracellular Ca^2+^ concentration or Ca^2+^ oscillations (Fig. [4](#prp2237-fig-0004){ref-type="fig"}, D--F). Because OAG augmented GSIS glucose dependently (Fig. [2](#prp2237-fig-0002){ref-type="fig"}C), the DAG/PKC pathway may potentiate GSIS by mechanisms independent of intracellular Ca^2+^.

Ca^2+^ influx and PKC activation elicit synergistic effects on insulin secretion with and without glucose {#prp2237-sec-0014}
---------------------------------------------------------------------------------------------------------

Our results indicated that IP~3~‐mediated Ca^2+^ release from ER downstream of FFAR1 acted as an amplifier of glucose‐induced Ca^2+^ oscillations, and that the effect of IP~3~ alone on GSIS was less potent than the effect of fasiglifam (Figs. [2](#prp2237-fig-0002){ref-type="fig"}B and [3](#prp2237-fig-0003){ref-type="fig"}). We also found that PKC activated by DAG could affect insulin secretion independent of Ca^2+^ dynamics (Fig. [4](#prp2237-fig-0004){ref-type="fig"}). We next investigated the importance of extracellular Ca^2+^ influx via an L‐type VDCC. The glucose‐dependent insulinotropic effect of fasiglifam in MIN6 cells was partially attenuated by 10 *μ*mol/L nifedipine, an L‐type VDCC blocker (Fig. [5](#prp2237-fig-0005){ref-type="fig"}A). This result implied that Ca^2+^ released from the ER, as well as Ca^2+^ coming from extracellular fluid through opened‐phase L‐type VDCC, might be critical for insulin secretion evoked by fasiglifam. This hypothesis was further studied by using *(S)*‐(‐)‐Bay K 8644, an L‐type VDCC opener, and examining its interaction with OAG on insulin secretion in the absence of glucose. Although there was only a slight increase in insulin secretion with either (*S*)‐(‐)‐Bay K 8644 or OAG alone, coadministration provoked a synergistic increase even in the absence of glucose (Fig. [5](#prp2237-fig-0005){ref-type="fig"}B and C). This result indicated that both elevated Ca^2+^ influx via opened‐phase L‐type VDCC, and PKC activation, may be critical for the overall insulinotropic effects of fasiglifam.

![Synergistic effects on insulin secretion elicited by the induction of Ca^2+^ influx and activation of protein kinase C. (A) Effects of nifedipine on the glucose‐stimulated insulin secretion potentiating effect of fasiglifam. Data are normalized to the vehicle (0 mmol/L glucose) group and shown as means ± SEM (*n* = 3). \*\*\**P* \< 0.001 versus 0 mmol/L glucose by Dunnett\'s test, ^\$^ *P* \< 0.05 by Welch\'s *t*‐test. (B) Dose--response effect of *(S)*‐(‐)‐Bay K 8644 (Bay) on insulin secretion in the absence of glucose in MIN6 cells. Data are normalized to the vehicle group and shown as means ± SEM (*n* = 3). \**P* \< 0.025 versus vehicle by one‐tailed Williams' test. (C) Dose--response effect of OAG, with and without 1 *μ*mol/L Bay, on insulin secretion in the absence of glucose in MIN6 cells. Data are normalized to the vehicle (neither OAG nor Bay) and shown as means ± SEM (*n* = 3). \**P* \< 0.025 versus vehicle by one‐tailed Williams' test. ^\#^ *P* \< 0.025 versus 1 *μ*mol/L Bay alone by one‐tailed Williams' test. Two‐way ANOVA: main effect of OAG: *P* \< 0.01; main effect of Bay: *P* \< 0.01; interaction of OAG and Bay: *P* \< 0.01.](PRP2-4-e00237-g005){#prp2237-fig-0005}

Discussion {#prp2237-sec-0015}
==========

Pancreatic *β*‐cells are equipped with various ion channels, pumps, transporters, and intracellular machinery to transduce nutrient signals into orchestrated responses that trigger insulin secretion (Rorsman and Braun [2013](#prp2237-bib-0029){ref-type="ref"}; Gilon et al. [2014](#prp2237-bib-0013){ref-type="ref"}). In the case of glucose, glucose uptake induces an increased ATP/ADP ratio, closure of the K~ATP~ channel, followed by plasma membrane depolarization, opening of L‐type calcium channels, and the subsequent influx of Ca^2+^ from the extracellular environment, which is the main pathway leading to insulin secretion. On the other hand, G*α*q‐mediated signals are well‐known to enhance GSIS (Fujiwara et al. [2005](#prp2237-bib-0011){ref-type="ref"}; Shapiro et al. [2005](#prp2237-bib-0032){ref-type="ref"}). Activation of G*α*q‐coupled receptors, such as FFAR1 and the muscarinic M~3~ receptor, stimulates the IP~3~/Ca^2+^ and DAG/PKC pathways and potentiates GSIS (Gilon and Henquin [2001](#prp2237-bib-0012){ref-type="ref"}; Fujiwara et al. [2005](#prp2237-bib-0011){ref-type="ref"}). FFAR1 selective agonists, such as fasiglifam, augment insulin secretion in a glucose‐dependent manner (Tsujihata et al. [2011](#prp2237-bib-0035){ref-type="ref"}; Yabuki et al. [2013](#prp2237-bib-0037){ref-type="ref"}), but the underlying mechanism behind the glucose dependency is not fully understood.

In this study, we first indicated the requirement of membrane depolarization for the insulinotropic action of fasiglifam (Fig. [1](#prp2237-fig-0001){ref-type="fig"}). Even in the absence of glucose, fasiglifam augmented insulin secretion when the membrane potential was forcibly depolarized. Yang et al. made a similar observation in which GW9508, a FFAR1/FFAR4 dual agonist, enhanced insulin secretion triggered by a SU in the absence of glucose (Yang et al. [2010](#prp2237-bib-0038){ref-type="ref"}). These results demonstrate that membrane depolarization induced by glucose metabolism, and subsequent events are essential for fasiglifam to enhance GSIS.

Amplitude and frequency are two key components of Ca^2+^ oscillations to evoke pulsatile insulin secretion in *β*‐cells (Smedler and Uhlen [2014](#prp2237-bib-0033){ref-type="ref"}). As it has not yet determined that the effect of fasiglifam or G*α*q signaling on Ca^2+^ oscillations, we analyzed it in Ca^2+^ imaging experiments. Frequency decoding of Ca^2+^ oscillations revealed that fasiglifam enhanced not only intracellular Ca^2+^ concentrations but also the amplitude of Ca^2+^ oscillations in a glucose‐dependent manner (Fig. [3](#prp2237-fig-0003){ref-type="fig"}A and B). However, the amplitude modulation of fasiglifam was common to all bandwidths examined, indicating that fasiglifam had no effects on the frequency modulation (Fig. [3](#prp2237-fig-0003){ref-type="fig"}C). The most likely physiological meaning of the amplitude enhancement by fasiglifam is the high secretory efficiency of insulin, but they can also affect Ca^2+^ homeostasis on various cellular organelles. For example, mitochondria, interacting with ER, contain several Ca^2+^‐dependent enzymes involved in the TCA cycle and ATP synthesis (Alam et al. [2012](#prp2237-bib-0001){ref-type="ref"}; Gilon et al. [2014](#prp2237-bib-0013){ref-type="ref"}). Thus, the enhanced amplitude by fasiglifam may affect glucose metabolism and promote ATP synthesis in mitochondria, leading to larger insulin secretion in the long term.

In contrast to fasiglifam, the SU drug, glimepiride, strongly mobilized Ca^2+^ even in the absence of glucose (Fig. [3](#prp2237-fig-0003){ref-type="fig"}D--F). SUs are often used as insulin secretagogues for the treatment of T2DM, but they have direct toxicity to *β*‐cells and the hypoglycemic risk in patients (Maedler et al. [2005](#prp2237-bib-0023){ref-type="ref"}). Our data can explain those drawbacks, in conjunction with the previous findings that sustained or excessive intracellular Ca^2+^ from the chronic use of SUs causes *β*‐cell apoptosis (Iwakura et al. [2000](#prp2237-bib-0016){ref-type="ref"}; Maedler et al. [2005](#prp2237-bib-0023){ref-type="ref"}).

To elucidate how the two major second messengers of FFAR1 affect Ca^2+^ dynamics and insulin secretion, we compared the effects of fasiglifam and analogs of IP~3~ or DAG. As we reported previously, the amount of IP~3~ produced in response to fasiglifam is independent of glucose concentrations (Tsujihata et al. [2011](#prp2237-bib-0035){ref-type="ref"}). Stimulation with the exogenous IP~3~ analog enhanced GSIS, intracellular Ca^2+^ levels, and the amplitude of Ca^2+^ oscillations similar to fasiglifam (Fig. [2](#prp2237-fig-0002){ref-type="fig"}A and B, Fig. [4](#prp2237-fig-0004){ref-type="fig"}A--C). These results indicate that the IP~3~ generated by FFAR1 plays a role in intracellular Ca^2+^ dynamics, which may contribute to augmented insulin secretion by fasiglifam.

Similar to fasiglifam, an exogenous DAG analog, OAG enhanced GSIS in a glucose‐dependent manner (Fig. [2](#prp2237-fig-0002){ref-type="fig"}A and C), consistent with a previous report using isolated mouse islets (Ferdaoussi et al. [2012](#prp2237-bib-0010){ref-type="ref"}). Importantly, OAG did not affect the glucose‐dependent Ca^2+^ oscillatory response unlike IP~3~ (Fig. [4](#prp2237-fig-0004){ref-type="fig"}D--F), indicating that the different mechanisms underlie the insulinotropic action of DAG. DAG activates PKC that then amplifies insulin granule exocytosis (Eliasson et al. [1996](#prp2237-bib-0009){ref-type="ref"}). Among 10 isoforms, PKC*α* and PKCε are most likely to play a role in DAG‐activated insulin secretion, supported by our findings that both abundantly expressed in MIN6 cells (Fig. S1). Recently, it has been reported that PKD, that is activated by DAG directly or indirectly via PKC, plays a role in FFAR1‐induced insulin secretion through its function on F‐actin depolymerization and cytoskeleton rearrangement (Kong et al. [2010](#prp2237-bib-0019){ref-type="ref"}; Ferdaoussi et al. [2012](#prp2237-bib-0010){ref-type="ref"}). Thus, PKD may also be involved in DAG‐induced insulin secretion in this study.

As shown in Figure [5](#prp2237-fig-0005){ref-type="fig"}A, Ca^2+^ influx from extracellular sites via an L‐type Ca^2+^ channel plays important roles in fasiglifam‐induced insulin secretion. Interestingly, the insulinotropic effects of (*S*)‐(‐)‐Bay K 8644 were synergistically stimulated with OAG in the absence of glucose (Fig. [5](#prp2237-fig-0005){ref-type="fig"}B and C). This observation indicates that DAG can potentiate the downstream insulin secretory pathways induced by Ca^2+^ influx. In addition, Ca^2+^ influx possibly enhances DAG‐mediated activation of Ca^2+^‐sensitive conventional PKCs including PKC*α* (Schmitz‐Peiffer and Biden [2008](#prp2237-bib-0031){ref-type="ref"}). Although the interaction between fasiglifam‐mediated IP~3~/Ca^2+^ pathway and Ca^2+^ influx from extracellular sites needs further investigation, the results of this study may provide insights into the entire process of FFAR1‐mediated insulin secretion.

In conclusion, we reinforce the roles of conventional G*α*q signal branches behind the glucose‐dependent action of fasiglifam, in parallel with recent reports regarding the roles of FFA metabolism and *β*‐arrestin signaling via FFAR1 (Kristinsson et al. [2015](#prp2237-bib-0020){ref-type="ref"}; Mancini et al. [2015](#prp2237-bib-0024){ref-type="ref"}). The pathways defined in this study are illustrated in Figure [6](#prp2237-fig-0006){ref-type="fig"}. We propose a dual potentiating model in which glucose‐induced extracellular Ca^2+^ influx through L‐type VDCC is augmented by both IP~3~‐mediated amplification of Ca^2+^ oscillations and PKC‐mediated augmentation of downstream secretory pathways, followed by FFAR1/G*α*q activation. Recently, state‐of‐the‐art [d]{.ul}esigner [r]{.ul}eceptors [e]{.ul}xclusively [a]{.ul}ctivated by [d]{.ul}esigner [d]{.ul}rug (DREADD) technology has proven that activation of G*α*q signaling maintains its effectiveness on *β*‐cells in a severe diabetic mouse model (Jain et al. [2013](#prp2237-bib-0017){ref-type="ref"}). Although fasiglifam was withdrawn from clinical trials due to liver safety concerns in December 2013, our findings are expected to help better characterize the utility of FFAR1 agonist therapy for the treatment of T2DM.

![Schematic dual potentiating model for fasiglifam‐induced FFAR1 signaling. Fasiglifam, a selective FFAR1 ago‐allosteric modulator, potentiates glucose‐stimulated insulin secretion in depolarized *β*‐cells via at least two distinct G*α*q‐mediated mechanisms: (1) fasiglifam‐induced IP~3~ production amplifies glucose‐induced Ca^2+^ oscillations, and (2) fasiglifam‐induced protein kinase C (PKC)/(PKD) protein kinase D activation augments downstream secretory mechanisms independent of Ca^2+^ oscillations.](PRP2-4-e00237-g006){#prp2237-fig-0006}
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